Human Va24 þ natural killer T (NKT) cells have an invariant T-cell receptor-a chain and are activated in a CD1d-restricted manner. Va24 þ NKT cells are thought to regulate immune responses and to play important roles in the induction of allograft tolerance. In this report, we analyzed the recovery of Va24 þ NKT cells after hematopoietic stem cell transplantation and its correlation with graft-versus-host disease (GVHD). Patients who received a dose-reduced conditioning regimen, antithymocyte globulin-or CAMPATH-1H-containing conditioning regimen were excluded. NKT cells were reconstituted within 1 month after transplantation in peripheral blood stem cell transplantation recipients, while their numbers remained low for more than 1 year in bone marrow transplantation (BMT) recipients. The number of Va24 þ NKT cells in BMT recipients with acute GVHD was lower than that in patients without acute GVHD, and both the CD4 þ and CD4 À Va24 þ NKT subsets were significantly reduced. With regard to chronic GVHD, BMT recipients with extensive GVHD had significantly fewer Va24 þ NKT cells than other patients. Furthermore, the number of CD4 þ Va24 þ NKT cells was also significantly reduced in patients with chronic extensive GVHD. Our results raise the possibility that the number of Va24 þ NKT cells could be related to the development of GVHD.
Immune reconstitution after hematopoietic stem cell transplantation has been studied by many researchers.
Natural killer (NK) cells are reconstituted within 1 month. While the number of CD8 þ T cells quickly returns to the normal range, the recovery of CD4 þ T cells can take a year or more. 1 In recipients of peripheral blood stem cells, T-cell counts are higher than those in marrow recipients in the first year after transplantation. However, there have been no reports on natural killer T-(NKT) cell reconstitution after hematopoietic stem cell transplantation. 2 NKT cells are a population of T cells that have NK cell markers such as NK1.1 (NKR-P1C) in mice or CD161 (NKR-P1A) in humans. Most NKT cells use an invariant T-cell receptor (TCR)-a chain (Va14-Ja18 in mice, Va24-Ja18 in humans) paired with Vb8, Vb7, or Vb2 in mice, or with Vb11 in humans. [3] [4] [5] [6] [7] Human invariant Va24 þ NKT cells as well as mouse invariant Va14 þ NKT cells are activated by synthetic glycolipids such as a-galactosylceramide in a CD1d-restricted manner. NKT cells produce both Th1 (such as interferon (IFN)-b or tumor necrosis factor (TNF)-a) and Th2 (such as interleukin (IL)-4, IL-5, IL-10, IL-13) cytokines. They can control immune responses to infection and some tumors. 8, 9 On the other hand, it is thought that their natural physiological role is immunoregulation, such that they regulate autoimmune diseases or allograft rejection. 8, 9 Graft-versus-host disease (GVHD) is one of the most important complications of hematopoietic stem cell transplantation. It has been shown in a mouse acute GVHD model that bone marrow NK1.1 þ T cells can suppress GVHD. 10 It has also been reported that CD8 þ , CD1d-independent NKT cells, can reduce GVHD in mice. 11 However, there have been no reports on whether or not invariant NKT cells can regulate GVHD.
In this report, we analyzed the recovery of human Va24 þ NKT cells after hematopoietic stem cell transplantation and its correlation with GVHD.
Patients, materials, and methods

Patients and donors
The patients' characteristics are shown in 
Flow cytometry analysis
Mononuclear cells were separated from blood samples by density-gradient centrifugation (Lymphoprep; AXIS-SHIELD PoC AS, Oslo, Norway). Cells were stained with fluorochrome-conjugated monoclonal antibodies (anti-CD3-FITC (clone UCHT1), anti-CD4-PC5 (clone 13B8.2), anti-TCR Va24-FITC (clone C15), and anti-TCR Vb11-PE (clone C21) (Immunotech, Marseille, France) and analyzed by a FACSCalibur apparatus using CellQuest software following the manufacturer's protocol (Becton Dickinson, San Jose, CA, USA). Lymphocytes were gated on forwardand side-scatter plots and the percentage of each lymphocyte subset was determined. The absolute lymphocyte count was determined by a clinical blood test. Each absolute lymphocyte subset count was calculated as the absolute lymphocyte count multiplied by the percentage of the lymphocyte subset divided by 100.
Chimerism of NKT Cells
Genomic DNA was extracted from Va24 and Vb11 double-positive cells, which were sorted from the peripheral blood of the recipients (by FACSVantage (Becton Dickinson)) and subjected to a short tandem repeat (STR)-PCR analysis as described previously. 12 Briefly, an STR fragment (D20S471 for pts. 002, 013, and 014, and D22S684 for pt. 003) that showed different allelic polymorphism in a given donor/recipient pair was PCR amplified from extracted DNA and analyzed by an ABI PRISM 377 DNA sequencer in combination with Genescan 3.1 software (Applied Biosystems, Foster City, CA, USA), with which different polymorphic peaks were separated and quantified to evaluate chimerism. Primer sequences were 5 0 -FAM GGGATGCAGAAATTGCAGTA and TTTTCTCTTTGCCACTGACC for D20S471, and 5 0 -HEX CCCTCTCCCTCTCTTACAGG and TTCTTAGT GGGGAAGGGATC for D22S684.
Statistical analysis
A statistical analysis was performed with the nonparametric Mann-Whitney U-test. A P-value of less than 0.05 was considered significant.
Results
Frequency of Va24 þ NKT cells in healthy donors
To measure Va24 þ NKT cells, we counted double-positive cells (Figure 1a) . Previous reports have shown that such 13, 14 and are CD1d dependent. 15, 16 The normal range of Va24 þ NKT cells is shown in Figure 1b . The values of the 25th, 50th, and 75th percentiles were 0.239, 0.552, and 1.345/ml, respectively. The median number as a percentage of total mononuclear cells was 0.026%, which was similar to the values in the previous reports.
16-18
Number of Va24 þ NKT cells varied according to the graft source There was a significant difference in the number of reconstituted NKT cells between BMT and PBSCT in the acute phase ( Figure 2a ) and chronic phase (data not shown). In univariate and multivariate analyses, the only variable associated with the number of NKT cells was the stem cell source (PB or BM) in the acute phase. In the chronic phase, similar results were obtained in a univariate analysis, but not in a multivariate analysis. (Variables evaluated included stem cell source (PB or BM, sibling or unrelated), diagnosis, HLA disparity, GVHD prophylaxis, with or without cytomegalovirus (CMV) viremia, GVHD, and with or without steroid treatment.) Since chronic-phase samples were collected between 150 and 1155 days after transplantation, the univariate and multivariate analyses also included time post transplant, but this was not considered as a variable. In BMT, NKT cells were not reconstituted within a year (Figure 2b ). In contrast, the number of NKT cells was within the normal range at 1 month after PBSCT (Figure 2c ). It was unclear as to whether the number of NKT cells in BMT patients would reach the normal range after 1 year.
We could analyze the chimerism of NKT cells in only four patients in the chronic phase (one received PBSCT and the others received BMT) by PCR-based assays of polymorphic STR markers. They all showed o10% recipient chimerism.
Number of Va24
þ NKT cells in patients with GVHD was lower than that in patients without GVHD in BMT Since the number of NKT cells in patients who received related BMT was not significantly different from that in patients who received unrelated BMT (data not shown), we analyzed related and unrelated BMT together. The number of Va24 þ NKT cells in BMT recipients without acute GVHD was significantly higher than that in BMT recipients with acute GVHD (Figure 3a) . Patients with GVHD were treated with steroids in many cases. Since lymphocytes are decreased when steroids are administered, the treatment of GVHD might reduce the number of NKT cells. However, the administration of steroids to patients with or without GVHD did not significantly affect the number of NKT cells (Figure 3b ). In addition, since Va24 þ NKT cells almost universally express inflammatory lymphocyte chemokine receptors, and these receptors may cause them to be distributed at sites of inflammation, 18 they may have been removed from the blood in GVHD patients. However, there was no correlation between CMV viremia and the number of NKT cells (Figure 3c) . Most of the Va24 þ NKT subsets are CD4 À CD8 À (double-negative: DN) and CD4 þ , although there is a small subset of the CD8 þ phenotype in peripheral blood. 14 Since there are so few CD8
þ NKT cells and since they are so similar to DN NKT cells, 14 we examined CD4 þ and CD4 À NKT cells. Both CD4
þ and CD4 À Va24 þ NKT cells were significantly reduced in patients with acute GVHD (Figure 3d ,e). Since there were so few patients with grade III or IV GVHD, we could not evaluate whether or not the severity of GVHD was correlated with the number of NKT cells.
Beyond 150 days after BMT, the number of Va24 þ NKT cells in chronic extensive GVHD patients was significantly lower than that in patients who had no or limited chronic GVHD (Figure 4a (Figure 4b ). There were also fewer CD4
À Va24 þ NKT cells in chronic extensive GVHD patients, but this difference was not significant (Figure 4c) . Again, the administration of steroids did not significantly affect the number of NKT cells (data not shown). Since the generation of murine Va14 þ NKT cells is thought to be thymus dependent, 9 NKT cell reconstitution in humans may also be thymus dependent. However, the number of NKT cells did not correlate with the number of CD3 T cells (Figure 4d) .
In PBSCT recipients, NKT cell counts in patients with GVHD were not significantly different than those in patients without GVHD (data not shown), although the number of NKT cells in patients without GVHD tended to be higher than that in patients with GVHD ( Figure 2c) .
As shown in Figure 2b , few GVHD patients with a normal NKT cell count on day 30 subsequently fell outside the normal range, and some patients showed the reverse trend (ie an abnormal NKT count became normal). Therefore, we examined NKT cell recovery and the timing of GVHD or other complications. Figure 5a shows NKT cell recovery in a 30-year-old male who received related BMT. He suffered from gut stage 3 acute GVHD. It was most severe on days 50 and 75, but subsided beginning on Figure 5b shows NKT cell recovery in a 34-yearold female who received unrelated BMT. She suffered from skin stage 3 GVHD on day 10. She received methylprednisolone pulse therapy and recovered quickly. She did not suffer from GVHD afterwards. Figure 5c shows NKT recovery in a 53-year-old female who received unrelated BMT. She suffered from skin stage 3 GVHD on day 17. Her GVHD responded to steroid treatment, but on day 100 she suffered from chronic lung GVHD. All of these cases suggest that GVHD may be correlated with a low number of NKT cells.
Discussion
In this study, we examined the recovery of Va24 þ NKT cells in patients who received hematopoietic stem cell transplantation and its correlation with GVHD. Many studies have suggested that an important physiological function of NKT cells is to control immune responses against infection and some tumors. In transplantation immunity, CD1d-dependent NKT cells are also thought to play a role in the induction of self 19 or allograft [20] [21] [22] or xenograft tolerance. 23 In a murine GVHD model, bone marrow DN NK1.1 þ T cells were observed to be important for preventing GVHD. 10 Recently, NKT cells that were CD1d independent or that had diverse TCR-a chains have been reported. CD8
þ CD1d-independent NKT cells have been shown to reduce GVHD. 11 Bone marrow noninvariant CD1d-restricted NKT cells that had the potential to suppress GVHD have been reported in humans. 17 However, to the best of our knowledge, there has been no previous report that human Va24 þ NKT cells prevented GVHD. In the present study, the number of Va24 þ NKT cells in BMT recipients with acute GVHD or chronic extensive GVHD was lower than that in recipients without 
GVHD. Thus, Va24
þ NKT cells may also function to suppress GVHD, although it is also possible that GVHD decreases the number of NKT cells. The administration of steroids, which is the most popular therapy for GVHD, did not suppress NKT cells. Moreover, the recovery of other lymphocytes (NK cells, B cells,
þ CD45RA þ T cells, and CD4 þ CD45RO þ T cells) was not significantly affected by the presence of acute or chronic GVHD (data not shown). Therefore, the low number of NKT cells in patients with GVHD did not result from a delay in lymphocyte recovery. Further analyses using animal models are needed to determine whether the reduced number of NKT cells is a cause or an effect of GVHD.
NKT cells consist of three subsets: DN, CD4 þ , and CD8 þ cells. CD4 þ NKT cells produce large amounts of IL-4, while CD4
À (DN and CD8 þ ) NKT cells selectively produce Th1 cytokines. 14, 15, 24 The numbers of both CD4 þ and CD4 À NKT cells were reduced in acute GVHD patients. It has been suggested that the Th1/Th2 balance influences the development of acute GVHD. For example, there are some reports that Th1 cells cause acute GVHD more efficiently than Th2 cells, and that Th2 cells suppress GVHD. [25] [26] [27] Other data have suggested that Th1 cytokines reduced acute GVHD or that Th2 cytokines worsened acute GVHD. [28] [29] [30] In any case, it may be important to regulate both Th1 and Th2 cytokines to control GVHD, and thus CD4 þ and CD4 À Va24 þ NKT cells likely play some roles in preventing acute GVHD.
In the case of chronic GVHD, there were significantly fewer CD4
þ Va24 þ NKT cells in patients with chronic extensive GVHD than in those with no or limited GVHD. There also tended to be fewer CD4 À Va24 þ NKT cells in chronic extensive GVHD patients, although this difference was not significant. In some reports, Th2 cytokines have been recognized as the principal mediators of chronic GVHD. 19, 26 The protective effect against GVHD was strictly dependent on IL-4 production from NKT cells. 10, 31 Moreover, CD4 þ Va24 þ NKT cells produce large amounts of IL-10, 25, 32 and NKT cell-derived IL-10 was essential for the differentiation of antigen-specific regulatory T cells in systemic tolerance. 33 Thus, CD4 þ NKT cells that produce Th2 cytokines may suppress the Th1 response and control GVHD.
Recent reports have shown that CD4 þ CD25 þ T cells suppress GVHD.
34 CD4 þ CD25 þ T cells are known to be immune regulatory cells and are essential for the induction and maintenance of self-tolerance and for the protection of autoimmunity. We failed to show that the number of CD4 þ CD25 þ T cells correlated with GVHD (data not shown). CD25 is also expressed when CD4 þ T cells are activated in GVHD. Therefore, it might be difficult to count only suppressor T cells.
In Japan, PBSCT is only available to patients who have a related donor, and thus BMT is performed for patients with an unrelated donor. On the other hand, many related hematopoietic stem cell transplantations are PBSCT (we think that this is why the incidence of relapse in the PBSCT À T-cell number. The ratio is smaller in chronic extensive GVHD patients (n ¼ 16) than in other patients (n ¼ 27) (P ¼ 0.0148). cGVHD, chronic GVHD.
Va24
þ NKT cells after SCT K Haraguchi et al group was higher than that in BMT recipients). Therefore, we cannot simply compare the reconstitution of NKT cells between PBSCT and BMT. However, the difference is so significant that we could safely conclude that the recovery of NKT cells in patients who received PBSCT is much faster than that in patients who received BMT. One possible reason is that PBSC grafts contain more NKT cells than BM grafts. A previous report showed that the number of Va24 þ invariant NKT cells in BM was comparable to or less than that in peripheral blood mononuclear cells. 17 These findings indicate that PBSC grafts contain many more Va24 þ NKT cells than BM grafts. Chimerism of invariant NKT cells in the chronic phase was donor type, but it is difficult to investigate chimerism in the early phase, especially after BMT because there are extremely few invariant NKT cells. In PBSCT, we failed to show that there were significantly fewer NKT cells in patients with GVHD. One possible reason is that there were very few patients in this study and another is that the number of NKT cells varied widely among individuals.
In conclusion, Va24
þ NKT cells were reconstituted rapidly in PBSCT recipients and slowly in BMT recipients. The number of Va24 þ NKT cells in patients with GVHD was lower than that in patients without GVHD, and the number of CD4 þ NKT cells in GVHD patients is especially low. Our results raise the possibility that the therapeutic administration of Va24 þ NKT cells or agalactosylceramide might ameliorate GVHD. Thus, NKT cells should be considered as an exciting new modality of cellular therapy for the regulation of undesirable immune responses. Va24 
